Literature DB >> 12471133

Cationic polypeptides are required for antibacterial activity of human airway fluid.

Alexander M Cole1, Hsiang-I Liao, Olga Stuchlik, Jason Tilan, Jan Pohl, Tomas Ganz.   

Abstract

In a search for direct evidence leading to the biological relevance of airway secretions in innate host defense, we characterized the antibacterial function of cationic polypeptides within minimally manipulated nasal fluid. In this study, we show that cationic antimicrobial polypeptides are responsible for most of the bactericidal activity of whole nasal fluid. The removal of cationic polypeptides using a cation-exchange resin ablated the activity of nasal fluid against Escherichia coli, Listeria monocytogenes, and Pseudomonas aeruginosa. By using a novel proteomic approach, we identified a dozen cationic peptides and proteins within nasal fluid, all of which either are known antimicrobial polypeptides or have other proposed roles in host defense. Of the three most abundant cationic polypeptides in nasal fluid, lysozyme was more effective than either lactoferrin or secretory leukoprotease inhibitor in restoring the antibacterial activity of the cationic polypeptide-depleted fluid against a mucoid cystic fibrosis isolate of P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12471133     DOI: 10.4049/jimmunol.169.12.6985

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Antimicrobial activity of PLUNC protects against Pseudomonas aeruginosa infection.

Authors:  Lina Lukinskiene; Yang Liu; Susan D Reynolds; Chad Steele; Barry R Stripp; George D Leikauf; Jay K Kolls; Y Peter Di
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

Review 2.  Proteomics for nasal secretion analysis.

Authors:  Begoña Casado
Journal:  Curr Allergy Asthma Rep       Date:  2004-05       Impact factor: 4.806

Review 3.  Lysozymes in the animal kingdom.

Authors:  Lien Callewaert; Chris W Michiels
Journal:  J Biosci       Date:  2010-03       Impact factor: 1.826

Review 4.  Modifications to the peptidoglycan backbone help bacteria to establish infection.

Authors:  Kimberly M Davis; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

5.  Alcohol use disorders affect antimicrobial proteins and anti-pneumococcal activity in epithelial lining fluid obtained via bronchoalveolar lavage.

Authors:  Ellen L Burnham; Jeanette Gaydos; Edward Hess; Robert House; Jacinta Cooper
Journal:  Alcohol Alcohol       Date:  2010-08-20       Impact factor: 2.826

6.  Antimicrobial lipids: novel innate defense molecules are elevated in sinus secretions of patients with chronic rhinosinusitis.

Authors:  Jivianne T Lee; Mike Jansen; Abebayehu N Yilma; Angels Nguyen; Robert Desharnais; Edith Porter
Journal:  Am J Rhinol Allergy       Date:  2010 Mar-Apr       Impact factor: 2.467

7.  Lysozyme secretion by submucosal glands protects the airway from bacterial infection.

Authors:  Rana Dajani; Yulong Zhang; Peter J Taft; Sue M Travis; Timothy D Starner; Ansgar Olsen; Joseph Zabner; Michael J Welsh; John F Engelhardt
Journal:  Am J Respir Cell Mol Biol       Date:  2005-03-03       Impact factor: 6.914

8.  Increased susceptibility to pulmonary Pseudomonas infection in Splunc1 knockout mice.

Authors:  Yanyan Liu; Marissa E Di; Hong Wei Chu; Xinyu Liu; Ling Wang; Sally Wenzel; Y Peter Di
Journal:  J Immunol       Date:  2013-09-18       Impact factor: 5.422

9.  Suppression of innate immunity by a nasal carriage strain of Staphylococcus aureus increases its colonization on nasal epithelium.

Authors:  Gerry A Quinn; Alexander M Cole
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397

10.  Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice.

Authors:  Cecilia G Clement; Scott E Evans; Christopher M Evans; David Hawke; Ryuji Kobayashi; Paul R Reynolds; Seyed J Moghaddam; Brenton L Scott; Ernestina Melicoff; Roberto Adachi; Burton F Dickey; Michael J Tuvim
Journal:  Am J Respir Crit Care Med       Date:  2008-04-03       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.